Results 91 to 100 of about 37,898 (281)

Use of Guideline-Recommended Heart Failure Drugs in High-, Middle-, and Low-Income Countries: A Systematic Review and Meta-Analysis

Global Heart
Optimal use of guideline-directed medical therapy (GDMT) can prevent hospitalization and mortality among patients with heart failure (HF). We aimed to assess the prevalence of GDMT use for HF across geographic regions and country-income levels.
Gautam Satheesh, Rupasvi Dhurjati, Laura Alston, Fisaha Tesfay, Rashmi Pant, Ehete Bahiru, Claudia Bambs, Anubha Agarwal, Sanne A. E. Peters, Abdul Salam, Isabelle Johansson   +10 more
doaj   +1 more source

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan

Journal of Cardiovascular Pharmacology and Therapeutics, 2022
Aim: Changes in QRS duration in patients with heart failure with reduced ejection fraction (HFrEF) after sacubitril/valsartan therapy is not fully understood.
Po-Lin Lin MD, Ying-Hsiang Lee MD, Lawrence Yu-Min Liu MD, PhD, Cheng-Ting Tsai MD, Ten-Fang Yang MD, Wei-Ru Chiou MD, Mu-Yang Hsieh MD, Hung-Yu Chang MD, Chun-Che Huang PhD   +8 more
doaj   +1 more source

Skeletal Muscle Contractile Function in Heart Failure With Reduced Ejection Fraction—A Focus on Nitric Oxide

Frontiers in Physiology, 2022
Despite advances over the past few decades, heart failure with reduced ejection fraction (HFrEF) remains not only a mortal but a disabling disease. Indeed, the New York Heart Association classification of HFrEF severity is based on how much exercise a ...
Lauren K. Park, Andrew R. Coggan, Linda R. Peterson   +2 more
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

The role of machine learning in the modern management of heart failure

Cardiologia Hungarica
Introduction: The use of machine learning is exploding in all areas of healthcare, including the diagnosis and treatment of heart failure. Supervised machine learning can help predict the onset of heart failure, establish the diagnosis, and even predict ...
Gáspár Dániel, Komlósi Ferenc, Bohus Gyula, Tóth Patrik, Sax Balázs, Heltai Krisztina, Vándor László, Becker Dávid, Merkely Béla, Nagy Klaudia Vivien   +9 more
doaj   +1 more source

The evolving role of adiponectin as an additive biomarker in HFrEF [PDF]

Heart Failure Reviews, 2016
Heart failure (HF) is a growing health problem. Despite improved management and outcome, the number of patients with HF is expected to keep rising in the following years. In recent research, adiponectin was shown to exert beneficial effects in the cardiovascular system, but the protein was also implicated in the development and progression of HF.
Andreas B. Gevaert, Tahnee Sente, An M. Van Berendoncks, Vicky Y. Hoymans, Christiaan J. Vrints   +4 more
openaire   +2 more sources

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Novel pathways of heart failure with preserved ejection fraction [PDF]

, 2016
INTRODUCTION: Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based ...
Li, Shanpeng
core   +2 more sources